论文部分内容阅读
目的:观察丁苯酞软胶囊治疗急性脑梗死的临床疗效及安全性。方法:将82例急性脑梗死患者随机分为对照组和丁苯酞治疗组,对照组给予指南制定的常规急性脑梗死治疗方案治疗,丁苯酞治疗组在对照组的基础上加用丁苯酞软胶囊。在患者入院时用药前及治疗2周及治疗后8周对受试者进行神经功能缺失评分和日常生活能力状态评分。结果:两组治疗后2周、8周时治疗组与对照组NIHSS评分,治疗后8周治疗组与对照组Barthel ADL指数评分有差异,具有统计学意义(P<0.05)。治疗组的总有效率(92%)高于对照组(82%)。且患者服用后无明显不良反应。结论:丁苯酞软胶囊与传统药物联用,应用于轻中度脑梗死急性期,可明显提高治疗效果,未见明显不良反应,可作为急性期脑梗死治疗安全有效的选择。
Objective: To observe the clinical efficacy and safety of butylphthalide soft capsule in the treatment of acute cerebral infarction. Methods: 82 patients with acute cerebral infarction were randomly divided into control group and butylphthalide treatment group, the control group given guidelines for the development of conventional acute cerebral infarction treatment program, butylphthalide treatment group in the control group based on the use of butyl benzene Phthalocyanine soft capsules. Subjects were scored for neurological deficit scores and daily living ability status before treatment and 2 weeks after treatment and 8 weeks after treatment. Results: The NIHSS score of the two groups at 8 weeks and 8 weeks after treatment was significantly lower than that of the control group at 8 weeks after treatment (P <0.05). The total effective rate (92%) in the treatment group was higher than that in the control group (82%). And no significant adverse reactions after taking the patient. Conclusion: Butylphthalide soft capsules combined with traditional drugs, used in acute stage of mild to moderate cerebral infarction, can significantly improve the therapeutic effect, no obvious adverse reactions, can be used as a safe and effective treatment for acute cerebral infarction.